INDP is trading 6.2% down at $3.33 following a sharp multi-day pullback and news of a $12 million private placement.
- The company entered into a $12 million private placement of common stock with non-U.S. accredited investors on June 17, 2026.
- Shares are under pressure as investors digest the dilution and capital-raising needs, which is typical for small-cap biotech stocks facing risk-off sentiment.
- The current decline extends a correction from a significant price spike observed last week.